At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 107 enrolled
Drug / intervention
Retifanlimabdrug
Likely dose
Retifanlimab 500 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
In Brief
A Phase 2 clinical trial evaluating Retifanlimab for Metastatic Merkel Cell Carcinoma. Completed, enrolled 107 participants across 65 sites in 12 countries.
Detailed Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Merkel Cell Carcinoma
CountriesAustralia, Canada, Czechia, France, Germany, Hungary, Italy, Poland, Spain, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJul 2018
Enrollment StartFeb 2019
Primary CompletionJan 2022
Study CompletionJun 2024
TodayJul 2026
First PostedJul 26, 2018
Enrollment StartFeb 25, 2019
Primary CompletionJan 21, 2022
Study CompletionJun 28, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 7.9 years ago
Interventions
Retifanlimabdrug
INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks